- ICH GCP
- EUs kliniske prøveregister
Siste forsøk
EudraCT Number: 2005-000217-35 | Sponsor Protocol Number: EpSSG RMS 2005 | Start Date: | ||||||
Sponsor Name: Rikshospitalet-Radiumhospitalet HF | ||||||||
Full Title: EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma | ||||||||
Medical condition: Rhabdomyosarkom (RMS) er en kreftform utgående fra muskelvev. RMS kan oppstå hvor som helst i kroppen og rammer folk i alle aldre. Behandlingen av RMS består av cellegift, operasjon og/eller strål... | ||||||||
|
||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: NO (Ongoing) NL (Completed) BE (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000259-28 | Sponsor Protocol Number: 54179060LYM3003 | Start Date: | |||||||||||
Sponsor Name: Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma. | |||||||||||||
Medical condition: Mature B-Cell Neoplasm | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) SE () | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004982-37 | Sponsor Protocol Number: NBK155/1/2020 | Start Date: | |||||||||||
Sponsor Name: MEDICAL UNIVERSITY OF GDAŃSK | |||||||||||||
Full Title: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome | |||||||||||||
Medical condition: NEPHROTIC SYNDROME | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001400-16 | Sponsor Protocol Number: 6-1/05/1 | Start Date: | ||||||
Sponsor Name: Riga Stradins university | ||||||||
Full Title: Investigation of pain syndrome and clinical-biochemical parameters in 7 to 18 years old children with acute uncomplicated appendicitis who received non-surgical treatment. | ||||||||
Medical condition: Pain syndrome in 7 to 18 years old children with acute uncomplicated appendicitis, who received non-surgical treatment. | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: LV (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020810-27 | Sponsor Protocol Number: IB-08-03 | Start Date: | ||||||
Sponsor Name: Laboratoires BOIRON | ||||||||
Full Title: Essai clinique contrôlé randomisé, multicentrique, évaluant l'efficacité de deux médicaments homéopathiques (Dopamine 5 CH et Serotoninum muriaticum 5 CH) chez l'enfant TDAH âgé de 3 à 7 ans (6 ans... | ||||||||
Medical condition: TDAH (Trouble Déficit de l'Attention Hyperactivité) | ||||||||
|
||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: FR (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001771-21 | Sponsor Protocol Number: XL184–311 | Start Date: | |||||||||||
Sponsor Name: Exelixis, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-... | |||||||||||||
Medical condition: Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior VEGFR-targeted therapy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) FR (Ongoing) AT (Ongoing) HU (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Ongoing) HR (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002012-23 | Sponsor Protocol Number: SL79.22 | Start Date: | |||||||||||
Sponsor Name: STALLERGENES | |||||||||||||
Full Title: A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-in... | |||||||||||||
Medical condition: Birch Pollen-induced Allergic Rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) FR (Ongoing) FI (Ongoing) DE (Ongoing) LT (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing) AT (Ongoing) LV (Ongoing) PL (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004704-38 | Sponsor Protocol Number: GBG70 | Start Date: | |||||||||||
Sponsor Name: GBG Forschungs GmbH | |||||||||||||
Full Title: Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with lo-cally advanced or operable breast cancer receiving taxane-anthracycline containing chemo-therapy (DAFNE st... | |||||||||||||
Medical condition: Patients with HER2-positive early breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004904-50 | Sponsor Protocol Number: GWEP15100 | Start Date: | |||||||||||
Sponsor Name: GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study. | |||||||||||||
Medical condition: Infantile Spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005375-91 | Sponsor Protocol Number: NN9535-4216 | Start Date: | |||||||||||
Sponsor Name: Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FI (Completed) DE (Completed) GB (Completed) SK (Completed) LV (Completed) LT (Completed) GR (Completed) ES (Completed) PT (Completed) HR (Completed) | |||||||||||||
Trial results: View results |